CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
Updated Mar 28, 2023 04:00 PM ET
After-Market: $43.85 0.00 (0.00%) 7:58 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
2-Buy of 5 2
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value F Growth F Momentum F VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
Learn more about Zacks Equity Research reports
About Net Income (TTM)
The company's trailing twelve month (TTM) Net Income is the company's total income (or profits) for the past twelve months. Net income is calculated by taking revenues and adjusting for the cost of doing business, depreciation, interest, taxes and other expenses.
CRSP 43.85 -0.50(-1.13%)
Will CRSP be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer
Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
Other News for CRSP
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Eledon Pharmaceuticals (ELDN) and Celcuity (CELC)
Interesting CRSP Put And Call Options For October 20th
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
Vertex, CRISPR Therapeutics ink licensing deal for diabetes therapies
Vertex Pharmaceuticals, Crispr Therapeutics enter CRISPR/Cas9 licensing pact